Clinicopathological Characteristics and Oncological Outcomes of Non-urothelial Bladder Carcinomas: A Multicenter Study
Yıl: 2021 Cilt: 20 Sayı: 2 Sayfa Aralığı: 96 - 106 Metin Dili: İngilizce DOI: 10.4274/uob.galenos.2020.1378 İndeks Tarihi: 21-05-2022
Clinicopathological Characteristics and Oncological Outcomes of Non-urothelial Bladder Carcinomas: A Multicenter Study
Öz: Objective: The incidence of non-urothelial bladder cancers is very low, so our knowledge about their treatment protocols and prognosis is limited. We evaluated the clinicopathological characteristics of 26 patients in three different clinics and aimed to determine the prognostic factors affecting oncological outcomes. Materials and Methods: Between January 2012 and October 2019, we retrospectively analyzed the data of twenty-six patients aged between 44-75 years who were diagnosed and treated due to non-urothelial bladder carcinomas in three clinics. Results: Among twenty-six cases, nineteen (73.1%) were male and seven (26.9%) were female. The mean age at diagnosis was 60.77±8.52. The most common presenting complaint was gross hematuria (84.6%). It was followed by lower urinary tract symptoms (38.4%). Histological types of tumors were squamous cell carcinoma (9 cases, 34.8%), adenocarcinoma (eight cases carrying different histopathologic subtypes: Mucinous, signet ring cell, plasmacytoid/signet ring cell mixed variant and signet ring cell containing osteoclast-like giant cell, 30.8%), small cell carcinoma (3 cases, 11.5%), large cell neuroendocrine carcinoma (2 cases, 7.7%), extra-gastrointestinal stromal tumor (1 case, 3.8%) and malignant undifferentiated mesenchymal tumor (1 case, 3.8%) and leiomyosarcoma (2 cases, 7.6%). At a median follow-up of 13 (2-42) months, the progression-free survival rate was 61.5%, while the overall survival rate was 46.1%. In Kaplan-Meier analysis, the median survival of all cases was found to be 16 (9-33) months. Overall survival times were lower in the presence of advanced (3-4) pathological stages (p=0.006) and higher (≥2) ECOG scores (p=0.005). Conclusion: In our cases, we observed that overall survival rates increased in patients undergoing multimodal treatments involving radical cystectomy compared to the bladder-sparing approach. The survival rates were higher in squamous cell carcinomas, while the rate of metastasis was higher in adenocarcinoma and neuroendocrine tumors. Up-staging rates after cystectomy were higher in adenocarcinomas, sarcomas and squamous cell carcinomas.
Anahtar Kelime: Klinikopatolojik Özellikler ve Onkolojik Ürotelyal Olmayan Mesane Karsinomlarının Sonuçları: A Çok Merkezli Çalışma
Öz: Amaç: Ürotelyal olmayan mesane kanserlerinin insidansı çok düşüktür, bu nedenle tedavi protokolleri ve prognozu hakkındaki bilgilerimiz sınırlıdır. değerlendirdik üç farklı klinikte 26 hastanın klinikopatolojik özellikleri ve onkolojik sonuçları etkileyen prognostik faktörlerin belirlenmesi amaçlanmıştır. Gereç ve Yöntem: Ocak 2012 ile Ekim 2019 tarihleri arasında 44-75 yaş arası 26 hastanın verilerini retrospektif olarak inceledik. üç klinikte ürotelyal olmayan mesane karsinomları nedeniyle teşhis ve tedavi edildi. Bulgular: Yirmi altı olgunun on dokuzu (%73.1) erkek, yedisi (%26.9) kadındı. Ortalama tanı yaşı 60,77±8.52 idi. En genel Başvuru şikayeti gros hematüri (%84.6) idi. Bunu %38,4 ile alt üriner sistem semptomları izlemekteydi. Histolojik tümör tipleri skuamöz hücreydi karsinom (9 olgu, %34.8), adenokarsinom (farklı histopatolojik alt tipleri taşıyan sekiz olgu: Müsinöz, taşlı yüzük hücresi, plazmasitoid/taşlı yüzük hücresi karışık varyant ve taşlı yüzük hücresi içeren osteoklast benzeri dev hücre, %30.8), küçük hücreli karsinom (3 vaka, %11.5), büyük hücreli nöroendokrin karsinom (2 vaka, %7,7), ekstragastrointestinal stromal tümör (1 vaka, %3,8) ve malign farklılaşmamış mezenkimal tümör (1 vaka, %3,8) ve leiomyosarkom (2 vaka, %7,6). 13 (2-42) aylık medyan takipte, progresyonsuz sağkalım oranı %61.5 iken, genel sağkalım oranı %46,1 idi. Kaplan-Meier analizinde, tüm olguların medyan sağkalımı 16 (9-33) ay olarak bulundu. İleri (3-4) patolojik evrelerin varlığında genel sağkalım süreleri daha düşüktü (p=0,006) ve daha yüksek (≥2) ECOG puanları (p=0,005). Sonuç: Olgularımızda radikal sistektomi içeren multimodal tedavi uygulanan hastalarda genel sağkalım oranlarının karşılaştırıldığında arttığını gözlemledik. mesane koruyucu yaklaşım. Skuamöz hücreli karsinomlarda sağkalım oranları daha yüksek iken, adenokarsinomlarda metastaz oranı daha yüksekti ve nöroendokrin tümörler. Adenokarsinomlar, sarkomlar ve skuamöz hücreli karsinomlarda sistektomi sonrası evreleme oranları daha yüksekti.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Kaur S, Gupta A, Gulwani HV. A clinicopathological and immunohistochemical study of non-urothelial bladder tumours. Indian J Cancer 2019;56:254-260.
- 2. Citgez S, Erözenci A, Yörükoğlu K. Non-ürotelyal mesane kanserleri. Bull Urooncol 2007;4:9-14.
- 3. Alanee S, Alvarado-Cabrero I, Murugan P, et al. Update of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladder. World J Urol 2019;37:107-114.
- 4. Cohen AJ, Packiam V, Nottingham C, et al. Upstaging of nonurothelial histology in bladder cancer at the time of surgical treatment in the National Cancer Data Base. Urol Oncol 2017;35:34.e1-34.e8. doi: 10.1016/j.urolonc.2016.08.002.
- 5. Erdem GU, Dogan M, Sakin A, et al. Non-urothelial bladder cancer: comparison of clinicopathological and prognostic characteristics in pure adenocarcinoma and non-bilharzial squamous cell carcinoma of the bladder. Oncol Res Treat 2018;41:220-225.
- 6. AJCC Cancer Staging Manual. 7th edition. 2010. p. 497-502.
- 7. Ravi K, Kumar T, Bakshi H, et al. Non urothelial bladder cancers: a case series. Indian J Surg Oncol 2013;4:2-8.
- 8. Abdollah F, Sun M, Jeldres C, et al. Survival after radical cystectomy of non-bilharzial squamous cell carcinoma vs urothelial carcinoma: a competing-risks analysis. BJU Int 2012;109:564-569.
- 9. Manunta A, Vincendeau S, Kiriakou G, et al. Non-transitional cell bladder carcinomas. BJU Int 2005;95:497-502.
- 10. Ploeg M, Aben KK, Hulsbergen-van de Kaa CA, et al. Clinical epidemiology of nonurothelial bladder cancer: analysis of the Netherlands Cancer Registry. J Urol 2010;183:915-920.
- 11. Dahm P, Gschwend JE. Malignant non-urothelial neoplasms of the urinary bladder: a review. Eur Urol 2003;44:672-681.
- 12. Izard JP, Siemens DR, Mackillop WJ, et al. Outcomes of squamous histology in bladder cancer: a populationbased study. Urol Oncol 2015;33:425.e7-13. doi: 10.1016/j.urolonc.2015.06.011.
- 13. Lagwinski N, Thomas A, Stephenson AJ, et al. Squamous cell carcinoma of the bladder: a clinicopathologic analysis of 45 cases. Am J Surg Pathol 2007;31:1777-1787.
- 14. Rogers CG, Palapattu GS, Shariat SF, et al. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol 2006;175:2048-2053; discussion 2053.
- 15. Zaghloul MS, Nouh A, Nazmy M, et al. Long-term results of primary adenocarcinoma of the urinary bladder: a report on 192 patients. Urol Oncol 2006;24:13-20.
- 16. Grignon DJ, Ro JY, Ayala AG, et al. Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer 1991;67:2165-2172.
- 17. Wright JL, Porter MP, Li CI, et al. Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder. Cancer 2006;107:721-728.
- 18. Zafuto E, Gazdovich S, Leyh-Bannurah SR, et al. Contemporary rates of pathological features and mortality for adenocarcinoma of the urinary bladder in the USA. Int J Urol 2017;24:117-123.
- 19. Roy S, Pradhan D, Ernst WL, et al. Next-generation sequencingbased molecular characterization of primary urinary bladder adenocarcinoma. Mod Pathol 2017;30:1133-1143.
- 20. Arslan B, Bozkurt IH, Yonguc T, et al. Clinical features and outcomes of nontransitional cell carcinomas of the urinary bladder: analysis of 125 cases. Urol Ann 2015;7:177-182.
- 21. Vincendeau S, de Lajarte-Thirouard AS, Bensalah K, et al. Neuroendocrine differentiation of bladder tumors. Prog Urol 2003;13:375-384.
- 22. Williams HA, Punjani N, Khan O, Power NE. The oncological outcomes of small cell carcinoma of the bladder. Can Urol Assoc J 2018;13:260-265.
- 23. Ou WT, Liang QL, Huang X, et al. Small cell carcinoma of the urinary bladder: a case report and review of the literature. Oncol Lett 2015;9:488-490.
- 24. Quek ML, Nichols PW, Yamzon J, et al. Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience. J Urol 2005;174:93-96.
- 25. Church DN, Bahl A. Clinical review - small cell carcinoma of the bladder. Cancer Treat Rev 2006;32:588-593.
- 26. Lohrisch C, Murray N, Pickles T, Sullivan L. Small cell carcinoma of the bladder: long term outcome with integrated chemoradiation. Cancer 1999;86:2346-2352.
- 27. Coelho HM, Pereira BA, Caetano PA. Large cell neuroen docrine carcinoma of the urinary bladder: case report and review. Curr Urol 2013;7:155-159.
- 28. Ayık E, Elpek Ö. Extragastrointestinal stromal tumors: localization and clinicopathological features. Turkiye Klinikleri J Med Pathol-Special Topics 2017;2:173-183.
- 29. He F, Fang Z, Zhu P, et al. Bladder extragastrointestinal stromal tumor in an adolescent patient: A case-based review. Mol Clin Oncol 2014;2:960-962.
- 30. Lee TK, Miyamoto H, Osunkoya AO, et al. Smooth muscle neoplasms of the urinary bladder: a clinicopathologic study of 51 cases. Am J Surg Pathol 2010;34:502-509.
| APA | SELVI I, Güven E, Kütükoğlu M, ÜRÜN Y, Tinay I (2021). Clinicopathological Characteristics and Oncological Outcomes of Non-urothelial Bladder Carcinomas: A Multicenter Study. , 96 - 106. 10.4274/uob.galenos.2020.1378 |
| Chicago | SELVI ISMAIL,Güven Eşref Oğuz,Kütükoğlu Mehmet umut,ÜRÜN YÜKSEL,Tinay Ilker Clinicopathological Characteristics and Oncological Outcomes of Non-urothelial Bladder Carcinomas: A Multicenter Study. (2021): 96 - 106. 10.4274/uob.galenos.2020.1378 |
| MLA | SELVI ISMAIL,Güven Eşref Oğuz,Kütükoğlu Mehmet umut,ÜRÜN YÜKSEL,Tinay Ilker Clinicopathological Characteristics and Oncological Outcomes of Non-urothelial Bladder Carcinomas: A Multicenter Study. , 2021, ss.96 - 106. 10.4274/uob.galenos.2020.1378 |
| AMA | SELVI I,Güven E,Kütükoğlu M,ÜRÜN Y,Tinay I Clinicopathological Characteristics and Oncological Outcomes of Non-urothelial Bladder Carcinomas: A Multicenter Study. . 2021; 96 - 106. 10.4274/uob.galenos.2020.1378 |
| Vancouver | SELVI I,Güven E,Kütükoğlu M,ÜRÜN Y,Tinay I Clinicopathological Characteristics and Oncological Outcomes of Non-urothelial Bladder Carcinomas: A Multicenter Study. . 2021; 96 - 106. 10.4274/uob.galenos.2020.1378 |
| IEEE | SELVI I,Güven E,Kütükoğlu M,ÜRÜN Y,Tinay I "Clinicopathological Characteristics and Oncological Outcomes of Non-urothelial Bladder Carcinomas: A Multicenter Study." , ss.96 - 106, 2021. 10.4274/uob.galenos.2020.1378 |
| ISNAD | SELVI, ISMAIL vd. "Clinicopathological Characteristics and Oncological Outcomes of Non-urothelial Bladder Carcinomas: A Multicenter Study". (2021), 96-106. https://doi.org/10.4274/uob.galenos.2020.1378 |
| APA | SELVI I, Güven E, Kütükoğlu M, ÜRÜN Y, Tinay I (2021). Clinicopathological Characteristics and Oncological Outcomes of Non-urothelial Bladder Carcinomas: A Multicenter Study. Üroonkoloji Bülteni, 20(2), 96 - 106. 10.4274/uob.galenos.2020.1378 |
| Chicago | SELVI ISMAIL,Güven Eşref Oğuz,Kütükoğlu Mehmet umut,ÜRÜN YÜKSEL,Tinay Ilker Clinicopathological Characteristics and Oncological Outcomes of Non-urothelial Bladder Carcinomas: A Multicenter Study. Üroonkoloji Bülteni 20, no.2 (2021): 96 - 106. 10.4274/uob.galenos.2020.1378 |
| MLA | SELVI ISMAIL,Güven Eşref Oğuz,Kütükoğlu Mehmet umut,ÜRÜN YÜKSEL,Tinay Ilker Clinicopathological Characteristics and Oncological Outcomes of Non-urothelial Bladder Carcinomas: A Multicenter Study. Üroonkoloji Bülteni, vol.20, no.2, 2021, ss.96 - 106. 10.4274/uob.galenos.2020.1378 |
| AMA | SELVI I,Güven E,Kütükoğlu M,ÜRÜN Y,Tinay I Clinicopathological Characteristics and Oncological Outcomes of Non-urothelial Bladder Carcinomas: A Multicenter Study. Üroonkoloji Bülteni. 2021; 20(2): 96 - 106. 10.4274/uob.galenos.2020.1378 |
| Vancouver | SELVI I,Güven E,Kütükoğlu M,ÜRÜN Y,Tinay I Clinicopathological Characteristics and Oncological Outcomes of Non-urothelial Bladder Carcinomas: A Multicenter Study. Üroonkoloji Bülteni. 2021; 20(2): 96 - 106. 10.4274/uob.galenos.2020.1378 |
| IEEE | SELVI I,Güven E,Kütükoğlu M,ÜRÜN Y,Tinay I "Clinicopathological Characteristics and Oncological Outcomes of Non-urothelial Bladder Carcinomas: A Multicenter Study." Üroonkoloji Bülteni, 20, ss.96 - 106, 2021. 10.4274/uob.galenos.2020.1378 |
| ISNAD | SELVI, ISMAIL vd. "Clinicopathological Characteristics and Oncological Outcomes of Non-urothelial Bladder Carcinomas: A Multicenter Study". Üroonkoloji Bülteni 20/2 (2021), 96-106. https://doi.org/10.4274/uob.galenos.2020.1378 |
